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A b s t r A c t
Common variable immunodeficiency (CVID) is the most common, clinically relevant, 
primary immunodeficiency (PID). In the western world the incidence of this disease 
is about 1:50000. CVID is characterized by hypogammaglobulinemia which involves 
in all cases immunoglobulin G (IgG), in about 70-80% of cases immunoglobulin A 
(IgA) and in about 50% of cases immunoglobulin M (IgM). Additionally, patients with 
CVID develop weak or no immunization responses against polysaccharide (mainly) 
and protein antigens. Clinical manifestations of CVID may present either early in 
childhood or late in adulthood, usually between the third and fourth decade of life. 
The range of CVID clinical manifestations is broad. Underlying CVID should be con-
sidered mainly in cases of patients who present with recurrent or persistent bacterial 
infections of the upper or lower respiratory tract. The possibility of underlying CVID 
has also to be examined during laboratory investigation of various clinical syndromes, 
such as lymphadenopathy, hepatosplenomegaly, chronic diarrhea, or malabsorption, 
and also of autoimmune cytopenias such as idiopathic thrombocytopenic purpura and 
autoimmune hemolytic anemia. It is noteworthy, that autoimmune diseases and ma-
lignancies in the form of lymphoma and neoplasm of the gastrointestinal tract occur 
with increased incidence in CVID patients in comparison to the general population. 
Treatment strategy of CVID patients should not be limited to immunoglobulin sub-
stitution therapy (administered either intravenously or subcutaneously), but it also has 
to target effective management of infections and early diagnosis of occurring malig-
nancies (lymphomas and gastrointestinal tumors) through systematic patient monitor-
ing. With regard to life expectancy of CVID patients, two recently published large 
retrospective studies showed that CVID patients suffering only from infections had 
prolonged overall survival compared to those who presented with other CVID clinical 
manifestations. Exclusion of all potential causes of secondary hypogammaglobuline-
mia is mandatory for establishing the diagnosis of CVID. Also, in some CVID cases, 
differential diagnosis from other PID may be required, such as X-linked agammaglob-
ulinemia (XLA), antibody deficiency with increased IgM (Hyper-IgM syndrome), and 
X-linked lymphoproliferative syndrome (XLP).
I N t r O D U c t I O N
Primary immunodeficiencies (PID) form a heterogeneous group of diseases char-
acterized by varying deficits, which relate commonly with specific immunity and are 
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located either in B-lymphocytes, or in T-lymphocytes, or both. 
Rarely may innate immunity deficits be responsible, in which 
case they are associated with phagocytes, NK cells, cytokine 
receptors and complement factors. According to the most 
recent classification of the International Union of Immuno-
logical Societies (IUIS) of 2004, which has been updated in 
2009, 2011 and 2014, PID are categorized into 8 groups, which 
are presented in Table 1.1-4 The vast majority of PID cases 
are diagnosed during childhood. Only a small fraction of PID 
cases are diagnosed in adulthood. These patients are almost 
exclusively suffering from primary antibody deficiencies, such 
as common variable immunodeficiency, selective immuno-
globulin A deficiency, selective deficiency of immunoglobulin 
G subclasses, or specific antibody deficiency.5,6 In adults, com-
mon variable immunodeficiency (CVID) attracts most of the 
interest, mainly because of its clinical heterogeneity (a disease 
with many faces). Herein, a brief presentation of CVID will 
be described, focusing on the range and the specific features 
of its clinical manifestations.
c O M M O N  v A r I A b L e 
I M M U N O D e F I c I e N c y  -  G e N e r A L  D A t A
Common variable immunodeficiency is characterized 
by hypogammaglobulinemia which in all cases concerns im-
munoglobulin G (IgG), in about 70-80% of cases it concerns 
immunoglobulin A (IgA) and in about 50% of cases it concerns 
immunoglobulin M (IgM). Additionally, patients with CVID 
develop weak or no immunization response against polysac-
charide (mainly) and protein antigens. CVID is the second 
most common primary antibody deficiency, after the selective 
deficiency of IgA, but the most common symptomatic antibody 
deficiency with an estimated incidence in about 1/50000.6-10 
Notably, the epidemiological data of almost all primary im-
munodeficiencies (including CVID) should be evaluated with 
caution, because they are considerably under diagnosed. In 
most CVID cases (approximately 85-90%) no inheritance 
is documented. In these patients causative mechanisms are 
practically unknown. In a minority of CVID patients with 
documented disease, inheritance with mutations in specific 
genes (CD19, ICOS, TACI, BAFFR, MSH5) associated with 
B-Lymphocyte ontogenesis and differentiation have been 
detected.6,11
The clinical manifestations of CVID may present either 
early in childhood or late in adulthood (usually between third 
and fourth decade of life).6-10 It is estimated that about 50% 
of CVID patients are diagnosed in adulthood. The range of 
CVID clinical manifestations is very broad (Table 2). Under-
lying CVID should be considered mainly in cases of patients 
who present with recurrent or persistent bacterial infections of 
the upper or lower respiratory tract (otitis, sinusitis, bronchitis, 
pneumonia), which are not adequately treated by common 
antibiotics.6-10 Also, young adults with chronic obstructive 
pulmonary disease or bronchiectasis should also be examined 
for underlying CVID. Additionally, the possibility of under-
lying CVID has to be examined during laboratory investiga-
tion of various clinical manifestations (lymphadenopathy, 
hepatosplenomegaly, chronic diarrhea, malabsorption) and 
autoimmune cytopenias, such as idiopathic thrombocytopenic 
purpura (ITP) and autoimmune hemolytic anemia (AHA).6,8,10 
It is noteworthy that autoimmune diseases and malignancies 
(lymphomas and neoplasms of the gastrointestinal tract) occur 
with increased incidence in CVID patients in comparison to the 
general population.6,8,10 Treatment strategy of CVID patients 
should not be limited to immunoglobulin substitution therapy 
(administered either intravenously or subcutaneously), but it 
also has to target effective management of infections and early 
diagnosis of occurring malignancies (lymphomas and gastro-
intestinal tumors) through systematic patient monitoring.6
As previously indicated, CVID clinical phenotype is both 
heterogeneous and complex.6-10 In the last few years, data from 
large patient registries have revealed that clinical phenotyping 
may aid in separating CVID patients into biologically relevant 
categories.10,12,13 Two main CVID clinical phenotypes were 
identified, CVID 1 characterized by infections and CVID 2 
in which inflammatory, autoimmune and/or hematologic com-
plications also develop.10,13 With regard to life expectancy of 
CVID patients, the same studies showed that CVID patients tAbLe 1. Classificationof Primary Immunodeficiencies 
(PID)
Combined T and B-cell immunodeficiencies
Congenital syndromes associated with specific immunity 
deficiencies
Predominantly antibody deficiencies
Diseases of immune dysregulation
Congenital defects of phagocyte function, number or both
Defects associated with innate immunity
Autoinflammatory disorders
Complement deficiencies
tAbLe 2. Clinical Manifestations of Common Variable 
Immunodeficiency
Respiratory disease
Gastrointestinal disease
Hematological complications
Autoimmune complications
Other complications
Malignancies
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suffering only from infections had prolonged overall survival 
compared to those who presented with some other clinical 
manifestations of CVID.10,12,13 Exclusion of all potential causes 
of secondary hypogammaglobulinemia is mandatory for es-
tablishing CVID diagnosis.14 Also, in some cases differential 
diagnosis of CVID from other PID may be required, such as 
X-linked agammaglobulinemia (XLA), antibody deficiency 
with increased IgM (Hyper-IgM syndrome), and X-linked 
lymphoproliferative syndrome (XLP).15
s e c O N D A r y 
H y P O G A M M A G L O b U L I N e M I A
The main groups of diseases including cases of patients 
who are likely to develop secondary hypogammaglobulinemia 
are malignant diseases, and protein-losing gastrointestinal or 
renal disorders. Also, therapeutic interventions often cause 
hypogammaglobulinemia.6,14
M A L I G N A N t  D I s e A s e s
From this group of diseases, hematologic malignancies 
mainly induce secondary hypogammaglobulinemia. Low-
grade lymphomas, especially chronic lymphocytic leukemia 
and follicular lymphoma, are well known causes of occasion-
ally severe hypogammaglobulinemia.6,14 The same applies to 
some multiple myeloma (MM) cases (light chain MM and 
non-secretory MM) and to several primary systemic (AL) 
amyloidosis cases.6,14 Finally, apart from the previously men-
tioned hematological malignancies, another known cause of 
occasionally severe hypogammaglobulinemia is thymoma. In 
these cases, hypogammaglobulinemia is not restored after 
surgical removal of the tumor.6,14
P r O t e I N - L O s I N G  D I s O r D e r s
It is well known that protein loss can occur via two main 
routes, the urinary and the gastrointestinal tract. Hence, 
hypogammaglobulinemia due to protein loss occurs mainly 
in cases of nephrotic syndrome, inflammatory bowel disease, 
intestinal lymphangiectasia (Waldman disease) and gastropa-
thy with protein loss (Menetrier syndrome).6,14 Malnutrition, 
a condition which is related to reduced protein intake and its 
increased catabolism, has also been associated with hypogam-
maglobulinemia.14 Finally, extensive burns and injuries have 
rarely been associated with hypogammaglobulinemia.14
t H e r A P e U t I c  I N t e r v e N t I O N s
Therapeutic interventions (transplants, drugs) have be-
come the major causes of secondary immunodeficiency.6,14 
Hematopoietic stem cell transplantation (HSCT) has been 
associated with disorders of all components of the immune 
system.16 Autologous HSCT (Auto-HSCT) is first or second 
line treatment option for patients suffering from several hema-
tological malignancies (multiple myeloma, Hodgkin’s disease, 
non-Hodgkin lymphoma). Allogeneic HSCT (Allo-HSCT) is 
a curative treatment option for several hematological malig-
nancies, especially for a large number of patients with acute 
leukemia who are in first or second complete remission.16 Due 
to myeloablative conditioning regimen, patients who undergo 
HSCT develop severe leukopenia which is restored usually 
quickly, but restoration in normal range of CD4 T-lymphocytes 
and B-lymphocytes is delayed. The result of sustained B-lym-
phopenia is the occurrence of hypogammaglobulinemia, which 
is further prolonged in patients undergoing Allo-HSCT (com-
pared with patients undergoing Auto-HSCT), both because 
of stronger myeloablation and immunosuppression resulting 
from the conditioning regimen, and because of immunosup-
pressive treatment against either acute or chronic graft versus 
host disease, or both.16 Patients undergoing organ transplant 
(especially renal transplantation), receive immunosuppressive 
treatment in order to prevent the occurrence of graft rejection. 
This immunosuppressive therapy has been associated with 
lymphopenia and hypogammaglobulinemia, mainly because of 
the effects of azathioprine and corticosteroids.14 Among medi-
cations, corticosteroids were probably the first ones associated 
with acquired immunodeficiency. Lymphopenia (absolute or 
selective) and hypogammaglobulinemia are well known con-
sequences of prolonged administration of corticosteroids.6,14 
The administration of monoclonal antibodies against CD20 
has been associated with both B-lymphopenia and prolonged 
hypogammaglobulinemia.14 Several drugs have been associated 
with secondary hypogammaglobulinemia, secondary selective 
IgA deficiency and secondary IgG subclasses deficiency.6,14 
Anti-infammatory (sulfasalazine, gold salts, chloroquine, 
D-penicillamine, non steroidal anti-inflammatory drugs) and 
anticonvulsant (phenytoin, carbamazepine, sodium valproate) 
drugs are included within this group.14 From the above, it is 
clear that primary consideration for adult patients presenting 
with hypogammaglobulinemia should be the exclusion of all 
possible causes of secondary immunodeficiency.
L A b O r A t O r y  I N v e s t I G A t I O N 
F O r  c O M M O N  v A r I A b L e 
I M M U N O D e F I c I e N c y  D I A G N O s I s 
D O c U M e N t A t I O N
Laboratory testing for CVID diagnosis documentation 
includes the following:
 A) Serum protein electrophoresis. Quantification of the major 
immunoglobulin classes (IgG, IgA, IgM); IgG subclasses 
quantification; anti-A and anti-B iso-hemagglutinin titra-
tion; evaluation of serum IgG antibody levels against 
bacterial polysaccharide and protein antigens, before and 
after immunization.6-8,10
 B) Total lymphocyte absolute number measurement; B, T and 
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NK cells measurement by flow cytometry (FC); T and B 
cells specific subpopulation (CD4, CD8, CD4/CD45RO, 
CD4/CD45RA, CD19/CD27, CD19/CD21) measurement 
also by FC. These subpopulations may exhibit alterations 
in CVID patients (in comparison with the general popu-
lation).6,8 Particularly, in many CVID patents’ peripheral 
blood, CD4/CD45RA T cells and CD19/CD27 B cells are 
low compared with the general population. Also, in some 
CVID patents’ peripheral blood, CD19/CD21 B cells may 
be detectable. Finally, testing should be done for CD40L 
(CD154) expression by FC too, if it is appropriate in certain 
cases.6,8
 C) Testing for the presence or the absence of specific proteins 
(BtK, SAP) by the Western blot technique, if it is appropri-
ate. 6,7,11
 D) Testing for the presence or the absence of mutations 
in specific genes (Btk, SH2D1A, CD40L) by molecular 
techniques.6,11 This specific laboratory testing and the 
aforementioned testing for the presence or the absence of 
specific proteins (BtK, SAP, CD40L) by FC and Western 
blot technique are helpful in order to distinguish CVID 
from other PID (XLA, Hyper-IgM syndrome, XLP), if 
necessary.
c L I N I c A L  P r e s e N t A t I O N  O F  c O M M O N 
v A r I A b L e  I M M U N O D e F I c I e N c y
The range of CVID clinical manifestations is broad, 
including acute and chronic infections, inflammatory and 
autoimmune diseases, and an increased incidence of cancer 
and lymphoma.6-10
r e s P I r A t O r y  D I s e A s e
Upper and lower respiratory tract infections (mainly due to 
polysaccharide encapsulated bacteria) are the most common 
clinical manifestations encountered in CVID patients (about 
70% of them), and in a significant proportion of them (about 
30%) the only ones present.6-10 Finally, with regard to the 
respiratory system, the presence of lung infiltrates (usually im-
aged by chest radiographs) is not uncommon. These infiltrates 
usually correspond to nonspecific granulomas (differential 
diagnosis of sarcoidosis is required), while rarely represent 
nonmalignant lymphoid infiltrates.6,8,10
G A s t r O I N t e s t I N A L  D I s e A s e
The remarkable probability of CVID diagnosis in the 
context of laboratory investigation for syndromes of chronic 
diarrhea (10-40% of cases) and malabsorption needs to be 
emphasized.6,8,10 Chronic diarrhea usually has an infectious 
etiology, due to Salmonella, Shigella, Cambylobacter, Crypto-
sporidium, or Giardia Lamblia.6 In some cases, differential 
diagnosis between CVID and diseases such as Crohn’s disease, 
ulcerative colitis and celiac disease accompanied by hypogam-
maglobulinemia, may be extremely difficult. Nodular lymphoid 
hyperplasia of the bowel (polyclonal hyperplasia of Peyer’s 
patches) is relatively common in CVID patients.6,8,10 Atrophic 
gastritis, with or without concomitant pernicious anemia, is less 
common in CVID patients. Liver involvement is not very com-
mon in CVID patients, and usually is associated with presence 
of nonspecific granulomas, presence of nodules in the context 
of modular regenerative hepatitis and presence of histological 
lesions compatible with primary biliary cirrhosis.6,8,10
H e M A t O L O G I c A L  c O M P L I c A t I O N s
Hematological complications of CVID are quite common. 
Splenomegaly is reported in about 30% of CVID cases and 
lymphadenopathy in about 10-20%, due to involvement with 
either nonmalignant lymphoid infiltrates or to development 
of granulomas.6,8,10 Regarding autoimmune cytopenias, occur-
rence of ITP is reported in about 10-30% of CVID cases.6,8,10 
Occurrence of AHA is less common. Finally, both Evans 
syndrome and autoimmune neutropenia are rarely diagnosed 
in CVID patients.6,8,10
A U t O I M M U N e  c O M P L I c A t I O N s
Apart from the aforementioned autoimmune cytopenias, 
the following autoimmune diseases have rarely been diagnosed 
during CVID: autoimmune thyroiditis, nonspecific arthritis 
clinically resembling rheumatoid arthritis, systemic lupus 
erythematosus and polymyositis-dermatomyositis.6,8,10
O t H e r  c O M P L I c A t I O N s
Very rarely has CVID been associated with the following 
disorders: allergy syndromes, central nervous system infec-
tions and degenerative diseases, urinary tract infections, op-
portunistic infections, cutaneous manifestations (infections, 
granulomas) and septic arthritis or osteomyelitis.6,8,10
M A L I G N A N c I e s
In the past 30 years, many studies established the associa-
tion between CVID and both lymphoma and gastrointestinal 
tract tumors. The cumulative risk of Hodgkin’s lymphoma and 
non-Hodgkin lymphoma affecting patients with CVID has 
been estimated to range between 2-9%. It has been estimated 
that among CVID patients, the incidence of lymphoma is 
about 30 times greater than in the general population. It has 
also been noted that among CVID patients, the incidence of 
gastric cancer is about 50 times greater than in the general 
population.6,8,10,12,13 
c O N c L U s I O N
As deduced from the data presented in this review, an 
integrated approach to CVID diagnosis requires a high index 
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of suspicion for an underlying immunodeficiency, exclusion 
of all potential causes of secondary hypogammaglobulinemia, 
profound knowledge of CVID clinical heterogeneity, special-
ized laboratory testing, and clearly distinguishing CVID from 
at least three other PID (XLA, Hyper-IgM syndrome, XLP).
r e F e r e N c e s
1. Notarangelo L, Casanova JL, Fischer A, et al. Primary Im-
munodeficiency Diseases: An Update. J Allergy Clin Immunol 
2004; 114:677-687.
2. Casanova JL, Chapel H, Conley ME, et al. Primary immu-
nodeficiencies: 2009 update. J Allergy Clin Immunol 2009; 
124:1161-1178.
3. Al-Hertz W, Bousfiha A, Casanova JL, et al. Primary Immu-
nodeficiency Diseases: An Update on the Classification from 
the International Union of Immunological Societies Expert 
Committee for Primary Immunodeficiency. Front Immunol 
2011; 2:1-26.
4. Al-Hertz W, Bousfiha A, Casanova JL, et al. Primary Immu-
nodeficiency Diseases: An Update on the Classification from 
the International Union of Immunological Societies Expert 
Committee for Primary Immunodeficiency. Front Immunol 
2014; 5:1-33.
5. Ress S. Immunodeficiency Diseases presenting in adults-
Diagnosis and Management. Curr Allergy Clin Immunol 
2008; 21:1-7.
6. Speletas M, Germenis A. Primary antibody deficiencies in 
adults: a contemporary clinical approach. Archives of Hellenic 
